All lobbying filings

W Strategies, LLC

W Strategies, LLC filed a Q3 report for Glaxosmithkline on October 19, 2026, reporting $40,000 in lobbying income.

Lobbying for Glaxosmithkline · Healthcare company.

As filed: W STRATEGIES, LLC for GLAXOSMITHKLINE.

All filings by W Strategies, LLC · Everything Glaxosmithkline has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 1

HOUSE OF REPRESENTATIVES

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Implementation of H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing. Education about FDA regulatory process.

Bills named in this filing 1

H.R. 5376
Impacts and Outcomes for Health Career Training Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.